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Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid
leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs
requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia
chromosome–positive (Ph1) chronic-phase (CP) CML. This systematic review of randomized
controlled trials (RCTs) compares the efficacy and safety of imatinib vs second-generation
(dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly
diagnosed Ph1 CP CML, concentrating on OS, progression-free survival (PFS), and
hematological and nonhematological adverse events. The quality of the evidence was
assessed using the Grading of Recommendations, Assessment, Development and Evaluation
(GRADE) method. Seven RCTs published between 1990 and 2019 (involving 3262
participants) satisfied the eligibility criteria. Two RCTs (imatinib vs nilotinib and imatinib vs
dasatinib) found no difference in 5-year OS or PFS. Second- and third-generation TKIs
improved 3-month major molecular responses (relative risk [RR], 4.28; 95% confidence
interval [CI], 2.20-8.32) and other efficacy outcomes, decreased accelerated/blastic-phase
transformations (RR, 0.44; 95% CI, 0.26-0.74), but were associated with more cases of
thrombocytopenia (RR, 1.57; 95% CI, 1.20-2.05), cardiovascular events (RR, 2.54; 95% CI, 1.49-
4.33), and pancreatic (RR, 2.29; 95% CI, 1.32-3.96) and hepatic effects (RR, 3.51; 95% CI 1.55-
7.92). GRADE showed that the certainty of the evidence ranged from high to moderate. This
study shows that, in comparison with imatinib, second- and third-generation TKIs improve
clinical responses, but the safer toxicity profile of imatinib may make it a better option for
patients with comorbidities.
Introduction
The overall incidence of chronic myeloid leukemia (CML) in Europe was 1.10 per 100000 in 2000 to
2002 (;4 per 100000 among patients aged 75-99 years)1,2 and, according to the population-based
registry of the European Treatment and Outcome Study (EUTOS), accelerated-phase (AP) and blastic-
phase (BP) CML, respectively, account for ;4% and 2% of diagnoses.3
Imatinib (Glivec; Novartis), the first tyrosine kinase inhibitor (TKI), completely changed patients’ life
expectancy.4 It was approved in 2001 (in Europe and the United States) for all CML phases and, as its
patent has expired, is now available as a generic drug.5
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Two second-generation TKIs, dasatinib (Sprycel; Bristol-Myers
Squibb) and nilotinib (Tasigna; Novartis), were approved in the
United States and Europe in 2006 to 2007 as second-line treatment
of patients resistant to, or intolerant of, previous treatment (including
imatinib): dasatinib was approved in all CML phases and nilotinib was
only approved in the chronic phase (CP) or AP.6-9 Since 2010 and
2011, both have been authorized for the first-line treatment of newly
diagnosed Philadelphia chromosome–positive (Ph1) adult CP
CML.10,11 Another second-generation TKI, bosutinib (Bosulif; Pfizer),
was licensed in the United States in 2012 and in Europe in 2013 for
the treatment of adults with CP, AP, or BP Ph1 CML who are
resistant to, or intolerant of, previous treatment with 1 or more
TKIs12-14; in December 2017, the indication was extended in the
United States to include newly diagnosed adult Ph1 CP CML.
The third-generation TKI, ponatinib (Iclusig; ARIAD), was approved
in the United States in 2012 and in Europe in 2013 for the treatment
of adults with CP, AP, or BP Ph1 CML who are resistant to, or
intolerant of, other TKIs; it was also approved for those with CP, AP,
or BP Ph1 CML and the T315I mutation, which is known to be
involved in resistance to imatinib.15,16
The introduction of TKIs has dramatically improved patient survival
from a median of 3 to 6 years before imatinib; now, CML is
considered a chronic disease. An update of the International
Randomized Study of Interferon and STI571 (IRIS) showed that the
estimated 10-year overall survival (OS) of imatinib-treated patients
was 83.3%,17 and most studies based on population cancer
registries have shown that 5-year survival has increased since TKIs
became available. The Girona population-based cancer registry
showed that 5-year relative survival in 1994 to 2008 was 80%
among CML patients treated with TKIs, and only 44% among those
not receiving TKIs.18 The European Cancer Registry-based Study
on Survival and Care of Cancer Patients 5 (EUROCARE-5) showed
that 5-year relative survival increased throughout Europe between
1997 and 2008 (particularly after 2000), although there were
considerable differences between countries.19 Survival increased in
all age groups, particularly among patients aged ,65 years, but
there was also a 10% increase among patients aged $75 years.19
However, other authors have found a smaller increase among the
elderly, possibly because of the underuse of imatinib and second-
generation TKIs (imatinib was received by 89.7% of the patients
aged 20-59 years, 75.0% of those aged 60-79 years, and 46.0% of
those aged $80 years).20
It is very difficult to define the best first-line TKI for treating adults
with newly diagnosed Ph1 CP CML. According to the 2017
European Society for Medical Oncology (ESMO) guidelines, the
decision should be based on treatment goals, age, comorbidities,
and the adverse event (AE) profile of the available drugs: 5-year
OS is similar among patients receiving first-line imatinib, dasatinib,
or nilotinib (85% to 95%) [I, A],21 and therapeutic goals should
be discussed with patients and defined before first-line drug
selection, taking age, comorbidities, and drug toxicity into account
[V, B].21 This is also in line with the 2018 National Comprehensive
Cancer Network (NCCN) guidelines, which include bosutinib as
an option for first-line treatment.22 However, if it is not possible to
demonstrate the advantage of 1 drug over another in a superiority
study, that does not mean that the 2 drugs are equal.
The aim of this study is to provide comprehensive, updated, and
precise information regarding the comparative efficacy and safety
of TKIs (imatinib vs dasatinib, nilotinib, bosutinib, ponatinib), with
particular emphasis on drug-related AEs.
Methods
Objectives
This systematic review and meta-analysis of randomized con-
trolled trials (RCTs) compares the efficacy and safety of imatinib
vs second-generation (dasatinib, nilotinib, bosutinib) and third-
generation (ponatinib) TKIs in adults with newly diagnosed Ph1 CP
CML. The considered outcomes were OS, progression-free survival
(PFS), response, and safety (hematological and nonhematological
AEs).
Study design
The review protocol is registered with the International Prospective
Register of Systematic Reviews (PROSPERO; registration no.
CRD42016032903),23 and the study was carried out in accor-
dance with Cochrane collaboration procedures and the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.24,25
Eligibility criteria
We considered published and unpublished RCTs comparing
imatinib at any dose with second-generation (dasatinib, nilotinib,
or bosutinib at any dose) or third-generation (ponatinib at any
dose) TKIs in adults aged $18 years old with newly diagnosed
(within the previous 6 months) CP CML and the Ph chromosome
in peripheral blood or bone marrow detected by means of
cytogenetics or fluorescent in situ hybridization, or the Abelson 1
(Abl1) oncogene with a breakpoint cluster region (Bcr) trans-
location (Bcr-Abl) detected by means of reverse transcription
polymerase chain reaction.1 The studies had to exclude patients
previously treated with a TKI (except those treated with imatinib
for no more than 2 weeks) and those receiving any other CML
medical treatment, except hydroxyurea and/or anagrelide, for
.2 weeks before study entry. Studies comparing imatinib with
any treatment other than TKI (eg, interferon-a, chemotherapy,
stem cell transplantation, or best supportive care) were excluded,
as were nonrandomized studies.
Trials for which it was unclear whether the method of randomization
provided adequate allocation concealment (quasi-RCTs) and open-
label RCTs were considered, but their quality was taken into
account.
Primary outcomes
OS and PFS were primary outcomes.
Secondary outcomes
Efficacy. Efficacy was determined by the following end points.
1. A complete cytogenetic response (CCyR) (ie, the absence of
Ph1 metaphases determined on the basis of G-banding in at
least 20 cells in metaphase per BM sample), and a confirmed
complete cytogenetic response (cCCyR) (ie, a documented
CCyR on 2 consecutive occasions separated by an interval of
at least 28 days), after 3, 12, 24, 36, 48, and 60 months of
treatment.
2. An early molecular response (EMR; Bcr-Abl International Scale
[IS] 5 10%) after 3 months of treatment.
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3. A major molecular response (MMR; Bcr-Abl IS 5 0.1%) after 3,
12, 24, 36, 48, and 60 months of therapy.
4. A molecular response 4 (MR4; Bcr-Abl IS 5 0.01%) and
molecular response 4.5 (MR4.5; Bcr-Abl IS 5 0.0032%) at any
time during treatment.
5. Transformation to AP and BP CML (excluding clonal evolution)
at any time during treatment.26
6. Treatment discontinuation at any time.
Safety. Safety was evaluated by grade 3-4 hematological AEs
(anemia, neutropenia, thrombocytopenia) at any time or by grade
3-4 nonhematological AEs (hypertension; cardiovascular events;
pulmonary arterial hypertension; pancreatic, hepatic, cutaneous
and gastrointestinal effects; fluid retention [pleural or pericardial
effusion]; bleeding; musculoskeletal disorders; neuropathy; ocular
toxicity; infectious events; metabolic syndrome; diabetes) at any time.
Searches
The PUBMED, EMBASE, Cochrane Central Register of Con-
trolled Trials (CENTRAL), and ClinicalTrials.Gov databases were
systematically searched for published or unpublished reports
in any language concerning RCTs or quasi-RCTs conducted
between 1990 and 28 May 2019, and their reference lists,
recent systematic reviews, meta-analyses, and guidelines were
examined for any other pertinent studies. We also screened the
abstracts of the main conferences in the field (the American
Society of Hematology [ASH], the American Society of Clinical
Oncology [ASCO], the European Haematology Association
[EHA], the Italian Society of Hematology [SIE]), and invited all
of the manufacturers of the TKIs in question to provide any
unpublished material.
The full electronic search strategy is described in the “Pubmed” and
“Embase Session Results” sections of the supplemental Data.
Study selection and data extraction
Two authors (C.V. and A.F.) independently screened the titles
and abstracts to identify potentially eligible papers, and confirmed
their eligibility by reading the full text. Publications concerning the
same RCT were collected, and the same authors independently
extracted the following information about each RCT: study year,
study design, and outcomes in the intervention and control arms.
Any disagreement was resolved by means of discussion with a third
reviewer (R.B.).
Risk-of-bias assessment and
quality-of-evidence grading
C.V. and A.F. independently assessed the studies using the
Cochrane risk-of-bias tool.27 The considered domains were selection
bias (sequence generation, allocation concealment), detection bias
(blinding of outcome assessors), performance bias (blinding of
participants and personnel), attrition bias (incomplete outcome data),
and reporting bias. The results were described using the risk-of-bias
summary (ie, authors’ judgement of each risk of bias for each study)
and the risk-of-bias graph (ie, authors’ judgements of each risk-of-bias
item presented as percentages of all studies), with the for-profit bias
under “other bias.”
The Grading of Recommendations Assessment, Development
and Evaluation (GRADE) method was used to assess the quality
of the evidence: that is, the extent to which we were confident that
the estimate of effect was correct.28 The evaluation considered
5 dimensions: study limitations (eg, the risk of bias), inconsis-
tency, indirectness, imprecision, and publication bias.28 The
grading was decreased by 1 (serious [21]) or 2 levels (very
serious [22]) in the case of a risk of bias, inconsistent study
results, uncertain directness (the correspondence between
population, intervention, or outcomes measured in the studies
actually found and those under consideration in our systematic
review),23 imprecise pooled estimates, and strongly suspected
publication bias (21).28
Strategy for data synthesis
Whenever available, we extracted data at different time points (eg,
3, 12, 18, 24, 36, 48, 60, and 72 months) from the intention-to-treat
analyses. Only aggregate qualitative and quantitative data were
summarized. For each study and outcome, a record was made of
the number of subjects in the control (imatinib) and intervention
group (dasatinib, nilotinib, bosutinib, ponatinib) and the number of
events. We used the preposition “by” to indicate cumulative
responses (the sum of events occurring between starting treatment
and the specified time point), and “at” to indicate the number of
events observed at the specified time point.
The data were pooled using the random-effects method (because
of the heterogeneity of the studies) and the Mantel-Haenszel
(M-H) method (because some studies had a small number of
patients and events). Hazard ratios (HRs) were used for OS
and PFS (Kaplan-Meier survival curves), and relative risk (RR),
or the risk ratio, for other dichotomous variables. Forest and
funnel plots were provided for each outcome included in the
meta-analysis.
Sensitivity analyses were used to establish the best threshold
for including secondary outcomes in the meta-analysis (the
minimum number of RCTs reporting a given outcome) on
the basis of the completeness of the information concerning
each outcome, and the meta-analysis value after removing that
outcome (data not shown). It was decided that a threshold of
5 should be used, which was applied to all outcomes before
pooling the data.
Study heterogeneity was evaluated by calculating the I2 statistic (I2),
with little, moderate, and substantial heterogeneity being, re-
spectively, indicated by I2 values of ,50%, 50% to 75%, and
.75%. Ninety-five percent confidence interval (CI) and 2-sided P
values were calculated for each result.
All of the analyses were made using Review Manager 5.3 statistical
software; the GRADE evidence profile was created on aGRADEpro
GDT platform.28
Results
Figure 1 shows the search strategy flowchart and the included and
excluded studies. Table 1 descriptively summarizes the included
studies.6-9,13,14,16,29-55 Only 2 RCTs reported OS and PFS up to
60 months (data not pooled), and only 1 reported OS up to 72
months.7,9,37,47-49 Five-year OS in the ENEST study was similar in
the imatinib and nilotinib groups (91.7% vs 93.7% for 300 mg of
nilotinib [HR, 0.80; 95% CI, 0.43-1.50], and 96.2% for 400 mg of
nilotinib [HR, 0.44; 95% CI, 0.21-0.93]), and the same was true
of 5-year PFS (91.0% vs, respectively, 92.2% [HR, 0.89; 95% CI,
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0.50-1.58] and 95.8% [HR, 0.44; 95% CI, 0.22-0.90]).9,47
Similar results were obtained in the DASISION study comparing
imatinib with dasatinib: 5-year OS, 90.0% vs 91.0% (HR, 1.01;
95% CI, 0.58-1.73), and 5-year PFS, 86.0% vs 85.0% (HR,
1.06; 95% CI, 0.68-1.66).7,37 The first follow-up (FU) time point
at which it would have been possible to analyze pooled OS and
PFS was 36 months (data available from 3 RCTs), but it was not
clinically relevant.6,7,9,34,44 Consequently, on the basis of the
proportional hazards assumption, we pooled the HRs roughly
extracted from the printed OS and PFS curves of Radich
et al (36-month FU) and the ENEST and DASISION HRs
(60-month FU), but the result was not statistically significant
(OS [HR, 0.78; 95% CI, 0.54-1.11]; PFS [HR, 0.85; 95% CI,
0.62-1.16]).6,7,9,37,47,56
PUBMED, EMBASE, the Cochrane Central Register
of Controlled Trials (CENTRAL) databases
346 abstracts 
Clinicaltrial.gov database
148 closed studies
237 open studies 
304 publications
excluded on the
basis of
title/abstract    
141 closed studies
236 open studies
excluded 
42 publications
(26 studies,16 systematic reviews/meta-analyses)
7 closed studies
1 open study 
29 studies
(potentially
relevant) 
17 systematic
reviews/meta-
analyses
(potentially
relevant)  
61 abstracts
from the reference
lists of the
selected articles
and reviews/meta-
analyses or
identified by hand
searches
(conference
proceedings,
clinical guidelines,
project sponsors)
10 studies excluded
on the basis of the full text   
5 systematic
reviews/meta-
analyses excluded
on the basis of the
full text 
46 abstracts
excluded
as duplicates  
19 relevant studies + 15 relevant abstracts
(corresponding to 7 RCTs)
Figure 1. Flowchart of search strategy.
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Table 1. Summary of the findings of the included studies
Follow-up, mo*,† Year/ref. Journal/full paper or abstract Outcome evaluated
RCT: DASISION (D); 519 patients
Imatinib: 49 (18-78) y; Male: 163 (63%)
Dasatinib: 46 (18-84) y; Male: 144 (56%)
12 2010/7 N Engl J Med/Full paper PFS 12 mo; OS 12 mo; CCyR by 3 mo, by 12 mo; cCCyR by 12
mo; MMR by 3 mo, by 12 mo; AP/BP; DIS
18 2010/29 Blood/Abstract PFS 18 mo; OS 18 mo; AP/BP
24 2011/30 J Clin Oncol/Abstract PFS 18 mo; OS 18 mo; MR4.5; AP/BP
24 2011/31 Blood/Abstract EMR at 3 mo; MMR by 3 mo, by 24 mo; MR4; MR4.5
24 2012/32 J Clin Oncol/Abstract MR4
24 2012/33 Blood/Full paper PFS 24 mo; OS 24 mo; CCyR at 12 mo, by 12 mo, at 24 mo, by 24
mo; cCCyR by 24 mo; MMR at 12 mo, by 12 mo, at 24 mo, by 24
mo; MR4.5; AP/BP; DIS
36 2014/34 Blood/Full paper PFS 36mo; OS 36mo; CCyR at 3 mo, at 12 mo, by 36 mo; cCCyR
by 36 mo; EMR at 3 mo; MMR at 12 mo, by 36; MR4; MR4.5;
AP/BP; DIS
48 2013/35 Blood/Abstract PFS 48 mo; OS 48 mo; EMR at 3 mo; MMR at 12 mo, by 48 mo;
MR4; MR4.5, AP/BP
60 2014/36 Blood/Abstract PFS 60 mo; OS 60 mo; cCCyR by 60 mo; EMR at 3 mo; MMR by
60 mo; MR4.5; AP/BP
60 2016/37 J Clin Oncol/Full paper PFS 60 mo; OS 60 mo; cCCyR at 60 mo; EMR at 3 mo; MMR by
12 mo, by 24 mo, by 36 mo, by 48 mo, by 60 mo, at 60 mo; MR4;
MR4.5; DIS
Quasi-RCT: NCT00070499 (D); 253 patients
Imatinib: 50 (19-89) y; Male: 72 (59%)
Dasatinib: 47 (18-90) y; Male: 74 (60%)
12 (36 mo for PFS, OS) 2012/6 Blood/Full paper PFS 36 mo; OS 36 mo; CCyR by 12 mo; MMR at 12 mo; MR4;
MR4.5; AP/BP; DIS
RCT: NordCML006 (D); 46 patients
Imatinib: 60 (38-77) y; Male: 15 (63%)
Dasatinib: 54 (29-71) y; Male: 7 (32%)
18 2013/38 Leukemia/Full paper CCyr at 12 mo
24 2013/39 Blood/Abstract MMR at 3 mo, by 12 mo, by 24 mo; MR4; MR4.5; AP/BP; DIS
36 2015/8 Eur J Haematol/Full paper CCyR at 3 mo, at 12 mo; EMR at 3mo; MR4; AP/BP; DIS
RCT: ENEST (N); 846 patients
Imatinib: 46 (18-80) y; Male: 158 (56%)
Nilotinib 300 mg: 47 (18-85) y; Male: 158 (56%)
Nilotinib 400 mg: 47 (18-81) y; Male: 175 (62%)
12 2010/40 J Clin Oncol/Abstract CCyR by 12 mo; MMR at 12 mo; MR4; MR4.5
12 2010/9 N Engl J Med/Full paper CCyR at 12 mo, by 12 mo; MMR at 3 mo, at 12 mo, by 12 mo;
MR4; MR4.5; AP/BP; DIS
18 2010/41 Blood/Abstract OS 18 mo; MR4.5; AP/BP
24 2011/42 Lancet Oncol/Full paper PFS 24 mo; OS 24 mo; CCyR by 12 mo, by 24 mo; MMR by 12
mo, by 24 mo; MR4; MR4.5; AP/BP; DIS
36 2012/43 Blood/Abstract PFS 36 mo; OS 36 mo; MMR by 36 mo; MR4; MR4.5
36 2012/44 Leukemia/Full paper PFS 36 mo; OS 36 mo; MMR at 36 mo, by 36 mo; MR4; MR4.5;
AP/BP; DIS
36 2013/45 Blood/Full paper AP/BP
48 2014/46 Blood/Full paper PFS 48 mo; OS 48 mo; EMR at 3 mo; MMR by 48 mo; MR4;
MR4.5; AP/BP
60 2016/47 Leukemia/Full paper PFS 60mo; OS 60 mo; EMR at 3 mo; MMR by 12mo, by 24 mo, by
36 mo, by 48 mo, by 60 mo; MR4; MR4.5; AP/BP; DIS
72 2015/48 Blood/Abstract MR4; MR4.5
72 2015/49 Haematologica/Abstract OS 72 mo; MMR by 72 mo; MR4.5
—, no data available; B, bosutinib; D, dasatinib; DIS, discontinued treatment; I, imatinib; N, nilotinib; P, ponatinib.
*In the row headings in column 1, RCTs and Quasi-RCTs included are: B, BEFORE (NCT02130557); B, BELA (NCT00574873); D, DASISION (NCT00481247); D (NCT00070499); D,
NordCML006 (NCT00852566); N, ENEST (NCT00471497); P, EPIC (NCT01650805).
†In the row subheadings in column 1, data are presented as: median age (range), y; male patients, number (percentage).
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Table 2 shows the pooled RRs of the second- and third-generation
TKIs in comparison with imatinib in terms of efficacy.9 As the ENEST
study reported the efficacy and toxicity data for each nilotinib dose,
we first pooled the 300 mg of nilotinib data relating to all of the
outcomes included in the meta-analysis (Table 2), then the 400 mg
of nilotinib data (Table 2), and then the mean values of the 2 doses
(Table 2) (sensitivity analysis).9 All of the pooled efficacy outcomes
except drug discontinuation showed that second- and third-
generation TKIs have a clear advantage over imatinib. In particular,
the RR of MMR after 3 months was statistically higher than that of
the other efficacy outcomes in the patients treated with second-
and third-generation TKIs (Figure 2). Moreover, treatment with
second- and third-generation TKIs clearly prevented AP and
BP transformation (Figure 3). All of the results were confirmed
Table 1. (continued)
Follow-up, mo*,† Year/ref. Journal/full paper or abstract Outcome evaluated
Quasi-RCT: BELA (B); 502 patients
Imatinib: 47 (18-89) y; Male: 135 (54%)
Bosutinib: 48 (19-91) y; Male: 149 (60%)
12 2012/13 J Clin Oncol/Full paper OS 12 mo; CCyR at 3 mo, at 12 mo, by 12 mo; MMR at 3 mo, at 12
mo, by 12 mo; AP/BP; DIS
18 2011/50 J Clin Oncol/Abstract CCyR at 12 mo, by 12 mo; MMR at 12 mo, by 12 mo; AP/BP
24 2014/51 Br J Haematol/Full paper OS 24 mo; CCyR at 24 mo, by 24; EMR at 3 mo; MMR at 24 mo,
by 24 mo; MR4; AP/BP; DIS
30 2012/52 Haematologica/Abstract OS 24 mo; CCyR by 24 mo; MMR by 24 mo; AP/BP
30 2014/53 Am J Hematol/Full paper —
48 2016/54 Am J Hematol/Full paper Only safety
RCT: BFORE (B); 536 patients
Imatinib: 53 (19-84) y; Male: 135 (56%)
Bosutinib: 52 (18-84) y; Male: 142 (58%)
12 2018/14 J Clin Oncol/Full paper OS 12 mo; CCyR by 12 mo; MMR at 3 mo, at 12 mo; MR4; MR4.5;
AP/BP; DIS
18 2017/55 Blood/Abstract OS 18 mo; AP/BP
Quasi-RCT: EPIC (P); 307 patients
Imatinib: 52 (18-86) y; Male: 92 (61%)
Ponatinib: 55 (18-89) y; Male: 97 (63%)
12 2016/16 Lancet Oncol/Full paper CCyR at 12 mo; EMR at 3 mo; MMR at 3 mo, at 12 mo; MR4;
MR4.5; DIS
—, no data available; B, bosutinib; D, dasatinib; DIS, discontinued treatment; I, imatinib; N, nilotinib; P, ponatinib.
*In the row headings in column 1, RCTs and Quasi-RCTs included are: B, BEFORE (NCT02130557); B, BELA (NCT00574873); D, DASISION (NCT00481247); D (NCT00070499); D,
NordCML006 (NCT00852566); N, ENEST (NCT00471497); P, EPIC (NCT01650805).
†In the row subheadings in column 1, data are presented as: median age (range), y; male patients, number (percentage).
Table 2. Pooled relative risk of second- and third-generation TKIs in comparison with imatinib by efficacy
Study
TKIs ENEST RCT: 300 mg TKIs ENEST RCT: 400 mg
TKIs ENEST RCT: mean values of 300 mg
and 400 mg
Outcome efficacy* No. of RCTs No. of pts RR† 95% CI† No. of RCTs No. of pts RR† 95% CI† No. of RCTs No. of pts RR† 95% CI†
EMR at 3 mo 6 2182 1.34 1.27-1.41 6 2184 1.33 1.27-1.40 6 2183 1.34 1.27-1.40
MMR at 12 mo 6 2208 1.52 1.32-1.75 6 2207 1.50 1.32-1.70 6 2208 1.51 1.32-1.73
MR4 at any time 7 2331 1.67 1.32-2.11 7 2330 1.60 1.31-1.96 7 2331 1.64 1.31-2.04
CCyR at 12 mo 5 1553 1.13 1.04-1.22 5 1552 1.13 1.04-1.22 5 1553 1.13 1.04-1.22
CCyR by 12 mo 5 2204 1.15 1.09-1.22 5 2203 1.15 1.09-1.20 5 2204 1.15 1.09-1.21
MMR at 3 mo 5 1823 4.50 2.23-9.09 5 1822 3.97 2.11-7.47 5 1823 4.28 2.20-8.32
MR4.5 at any time 6 1930 2.65 1.44-4.88 6 1929 2.58 1.42-4.70 6 1930 2.63 1.43-4.82
AP/BP during study treatment 6 2411 0.43 0.25-0.73 6 2410 0.44 0.26-0.74 6 2411 0.44 0.26-0.74
Discontinued any time 7 2715 1.00 0.81-1.24 7 2714 1.00 0.80-1.25 7 2715 1.00 0.80-1.24
Sensitivity analysis of different nilotinib doses (ENEST RCT: 300 mg, 400 mg, and mean values of 300 mg and 400 mg) (bosutinib BEFORE [NCT02130557], bosutinib BELA
[NCT00574873], dasatinib DASISION [NCT00481247], dasatinib [NCT00070499], dasatinib NordCML006 [NCT00852566], nilotinib ENEST [NCT00471497; 300-mg and 400-mg
doses], and ponatinib EPIC [NCT01650805]). In ENEST RCT, the patients (pts) were randomly assigned to receive 300 mg of nilotinib (n 5 282), 400 mg of nilotinib (n 5 281), 400 mg of
imatinib (n 5 283); the number of events is presented for the 3 groups (300 mg of nilotinib, 400 mg of nilotinib, 400 mg of imatinib). The sensitivity analysis was made by introducing into the
meta-analysis: first, the results of 300 mg of nilotinib; second, the results of 400 mg of nilotinib; and third, the arithmetic mean of the results of the 2 nilotinib doses.
*M-H method, random-effects method.
†Bold values in these columns are statistically significant.
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by the sensitivity analyses of the nilotinib doses (supplemental
Figures 1-9).
Table 3 shows the pooled RRs of second- and third-generation TKIs
in comparison with imatinib in terms of toxicity.9 Thrombocytopenia,
cardiovascular events, and pancreatic and hepatic effects were
more frequent among the patients treated with second- and third-
generation TKIs and, once again, all of the results were confirmed by
sensitivity analyses of the different nilotinib doses. Fluid retention
was also more frequent in the patients treated with second- and
third-generation TKIs, but the sensitivity analyses confirmed the
results only in the case of 300 mg of nilotinib (Table 3) and the mean
values of the results obtained using the 2 nilotinib doses (Table 3),
but not in the case of 400 mg of nilotinib (Table 3) (supplemental
Figures 10-21).9
Supplemental Figures 22 and 23, respectively, show the risk-of-bias
summary and graph, with the for-profit bias under “other bias.” All of
the articles were at low risk except for the risk-of-performance bias
(although it must be remembered that blinding trial participants and
study personnel may not be ethical in an oncological setting) and
the risk of “other bias” (6 of the 7 trials [85.7%] were sponsored by
a pharmaceutical company).
Supplemental Tables 1 and 2 show the GRADE quality of evidence
by efficacy and toxicity.28 The certainty of efficacy (the extent to
Favours [imatinib] Favours [new TKIs]
A
New TKIs Imatinib
Study or Subgroup
Bosutinib BEFORE NCT02130557
Bosutinib BELA NCT00574873
Dasatinib NordCML006 NCT00852566
Nilotinib ENEST (NCT00471497) (mean 300 mg 400 mg)
10
18
8
20
25
14
34
95 20
246 4 241 19.7% 2.45 [0.78, 7.70]
2.27 [1.00, 5.12]
4.36 [1.04, 18.37]
6.69 [2.01, 22.26]
8.36 [2.55, 27.38]
4.70 [1.37, 16.18]
11.85 [3.75, 37.47]
4.50 [2.23, 9.09]
26.6%
15.1%
0.0%
19.0%
0.0%
19.6%
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914
114
8
2
3
3
3
3
250
22
282
282
281
109
909 100.0%
Nilotinib ENEST NCT00471497 (300 mg)
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Ponatinib EPIC NCT01650805
Total (95% CI)
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= 0.31; Chi2
 
= 7.85, df = 4 (P = 0.10); I2
 
= 49%
Test for overall effect: Z = 4.20 (P < 0.0001)
Events Total
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M-H, Random, 95% CI
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M-H, Random, 95% CI
0.01 0.1 1 10 100
Events Total Weight
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Dasatinib NordCML006 NCT00852566
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84 20
246 4 241 19.6% 2.45 [0.78, 7.70]
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14.3%
0.0%
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Total (95% CI)
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Test for overall effect: Z = 4.28 (P < 0.0001)
Events Total
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M-H, Random, 95% CI
Risk Ratio
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0.01 0.1
Favours [imatinib] Favours [new TKIs]
1 10 100
Events Total Weight
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Dasatinib NordCML006 NCT0085266
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8
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4.36 [1.04, 18.37]
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4.70 [1.37, 16.18]
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Figure 2. Tables and forest plots of MMR at 3 months. ENEST RCT sensitivity analysis: 300 mg and 400 mg of nilotinib and mean values of 300 mg and 400 mg of
nilotinib. Nilotinib ENEST (NCT00471497; 300 mg and 400 mg). In ENEST RCT, the patients were randomly assigned to receive 300 mg of nilotinib (n 5 282), 400 mg of
nilotinib (n 5 281), 400 mg of imatinib (n 5 283); the number of events is presented for the 3 groups (300 mg of nilotinib, 400 mg of nilotinib, 400 mg of imatinib). The
sensitivity analysis was made by introducing into the meta-analysis: first, the results of 300 mg of nilotinib (A); second, the results of 400 mg of nilotinib (B); and third, the
arithmetic mean of the results of the 2 nilotinib doses (C). df, degrees of freedom.
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which we are confident that the estimates of effect are sufficient to
support a particular recommendation) was considered to be high
(further research is very unlikely to change our confidence in the
estimates of effect) in the case of EMR after 3 months, MMR after 3
and 12 months, MR4 at any time, CCyR by 12 months, and AP/BP
during study treatment; and it was moderate (further research is
likely to have a major impact on our confidence in the estimates of
effect and may actually change them) in the case of CCyR after 12
months, MR4.5 at any time, and discontinuation at any time. The
certainty of toxicity was high in the case of anemia, thrombocyto-
penia, musculoskeletal disorders, and QT prolongation; moderate in
the case of neutropenia, cardiovascular events, cutaneous effects,
fluid retention, infectious events, and pancreatic and hepatic
effects; and low in the case of gastrointestinal effects (further
research is very likely to have an important impact on our confidence
in the estimate of effect and is likely to change them).
The GRADE quality-of-evidence profiles (supplemental Tables 1
and 2) only considered the RRs of the mean values of the results
obtained using the 2 nilotinib doses (Tables 2 and 3 column 3).9,28
Discussion
Although many studies have compared the use of imatinib and more
recent TKIs in patients with newly diagnosed Ph1 CP CML, they
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Figure 3. Tables and forest plots of AP and BP transformations during study treatment. ENEST RCT sensitivity analysis: 300 mg of nilotinib, 400 mg of nilotinib, and
mean values of 300 mg and 400 mg of nilotinib. Nilotinib ENEST (NCT00471497; 300 mg and 400 mg). In ENEST RCT, the patients were randomly assigned to receive
300 mg of nilotinib (n 5 282), 400 mg of nilotinib (n 5 281), 400 mg of imatinib (n 5 283); the number of events is presented for the 3 groups (300 mg of nilotinib, 400 mg
of nilotinib, 400 mg of imatinib). The sensitivity analysis was made by introducing into the meta-analysis: first, the results of 300 mg of nilotinib (A); second, the results of
400 mg of nilotinib (B); and third, the arithmetic mean of the results of the 2 nilotinib doses (C).
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have not established which is the most efficacious because: they
have not always considered the same outcomes and often
evaluated them at different times, they only some provided complete
OS and PFS data, and the large number of AEs is not specific to
a single TKI.6-9,13,14,16 Furthermore, the 2017 ESMO and 2018
NCCN CML guidelines do not make any precise recommendations
that would help clinicians decide.21,22
Our systematic review and meta-analysis of RCTs provides
complete, updated, and precise comparative information con-
cerning the use of TKIs in patients with newly diagnosed adult
CP CML in terms of OS and PFS at various time points, clinical
and biological response variables, and the most relevant hemato-
logical and nonhematological AEs. Biases and the quality of the
evidence were assessed using the Cochrane risk-of-bias tool and
the GRADE method,27,28 and the 2 databases created are available
for purposes of data sharing.
As only 2 RCTs considered OS and PFS for up to 60 months, we
could not make a pooled analysis. However, the ENEST study found
that 60-month OS and PFS among the patients treated with
imatinib were, respectively, 91.7% and 91.0%, whereas the patients
treated with 300 mg or 400 mg of nilotinib had OS of, respectively,
93.7% and 96.2%, and PFS of 92.2% and 95.8%. The DASISION
study recorded 90% and 86% in imatinib-treated patients and 91%
and 85% in dasatinib-treated patints.7,9,37,47
Our meta-analysis clearly showed that, in terms of secondary efficacy
outcomes, second and third-generation TKIs were better in patients
with newly diagnosed CP CML without comorbidities, whereas
imatinib should be preferred for patients with comorbidities because
of its toxicity profile. These conclusions were supported by the
GRADE assessment of the quality of the evidence.28 However, AEs
can also occur in patients without preexisting comorbidities.
The fact that only 2 of the 7 RCTs satisfying our meta-analysis
eligibility criteria considered OS and PFS up to 60 months is
a major limitation of our study6-9,13,14,16,37,47 because, despite what
was laid down in the registered statistical plan,23 our conclusions
only take secondary outcomes into account. However, the absence
of such strong efficacy outcomes as OS and PFS is frequent in the
literature: many trials use surrogate outcomes, which explains why
postmarketing studies of cancer drugs have revealed limited
benefits in terms of OS or the quality of life.57
Other authors have tried to define the best first-line TKI for treating
CP CML by means of systematic reviews and meta-analyses, but
their conclusions have been less useful in clinical practice than
expected.58-64 Our findings are in line with previously published
results but are more complete as they relate to all 5 TKIs currently
approved for the first-line treatment of CP CML in Europe or the
United States (ie, imatinib, dasatinib, nilotinib, bosutinib, and
ponatinib), they are updated to May 2019, they consider multiple
outcomes (efficacy and toxicity, particularly individual hematological
and nonhematological AEs), the original protocol was registered
with PROSPERO to avoid the risks of selection and publication
bias,23 and biases and the quality of the evidence were assessed
using the Cochrane risk-of-bias tool and GRADE profiles.27,28
The network meta-analysis by Mealing et al compared the results
obtained using first-line imatinib with those obtained using high-
dose imatinib, nilotinib, or dasatinib in studies published up to March
2011 (including 8 RCTs), and showed an advantage in using
second-generation TKIs on the basis of 12-month CCyR and
MMR.58 However, they did not evaluate essential outcomes such as
AEs, and the selection of patients is not clear.58
The study by Gurion et al comparing the results obtained using first-
line imatinib with those obtained using nilotinib, dasatinib or
Table 3. Pooled relative risk of second- and third-generation TKIs, in comparison with imatinib by toxicity
Study
TKIs ENEST RCT: 300 mg TKIs ENEST RCT: 400 mg
TKIs ENEST RCT: mean values of 300 and
400 mg
Outcome toxicity: grade 3-4*,† No. of RCTs No. of pts RR‡ 95% CI‡ No. of RCTs No. of pts RR‡ 95% CI‡ No. of RCTs No. of pts RR‡ 95% CI‡
Anemia 7 2704 1.17 0.80-1.72 7 2702 1.20 0.86-1.69 7 2703 1.19 0.83-1.70
Neutropenia 7 2704 0.69 0.46-1.02 7 2702 0.68 0.45-1.01 7 2703 0.68 0.46-1.02
Thrombocytopenia 7 2704 1.55 1.17-2.05 7 2702 1.58 1.22-2.06 7 2703 1.57 1.20-2.05
Cardiovascular events 7 2704 2.26 1.32-3.87 7 2702 2.75 1.62-4.67 7 2703 2.54 1.49-4.33
Cutaneous effects 7 2704 0.73 0.21-2.47 7 2702 1.03 0.35-2.98 7 2703 0.93 0.32-2.75
GI effects 7 2704 1.80 0.67-4.84 7 2702 2.02 0.84-4.86 7 2703 1.94 0.77-4.85
Fluid retention§ 7 2704 3.21 1.09-9.48 7 2702 2.81 0.99-7.97 7 2703 3.11 1.07-9.00
Infectious events 7 2704 1.11 0.54-2.28 7 2702 1.12 0.49-2.56 7 2703 1.11 0.54-2.28
Pancreatic effects 5 2413 2.24 1.29-3.87 5 2411 2.31 1.33-4.02 5 2412 2.29 1.32-3.96
Hepatic effects 6 2459 3.01 1.21-7.51 6 2457 3.89 1.81-8.35 6 2458 3.51 1.55-7.92
Musculoskeletal disorders 6 2658 0.76 0.36-1.62 6 2656 0.92 0.46-1.83 6 2657 0.85 0.42-1.73
QT prolongation 5 2352 0.82 0.39-1.73 5 2350 0.82 0.39-1.74 5 2351 0.82 0.39-1.73
Sensitivity analysis of different nilotinib doses (ENEST RCT: 300 mg, 400 mg, and mean values of 300 mg and 400 mg) (bosutinib BEFORE [NCT02130557], bosutinib BELA
[NCT00574873], dasatinib DASISION [NCT00481247], dasatinib [NCT00070499], dasatinib NordCML006 [NCT00852566], nilotinib ENEST [NCT00471497; 300-mg and 400-mg
doses], ponatinib EPIC [NCT01650805]). In ENEST RCT, the patients were randomly assigned to receive 300 mg of nilotinib (n 5 282), 400 mg of nilotinib (n 5 281), 400 mg of imatinib
(n 5 283); the number of events is presented for the 3 groups (300 mg of nilotinib, 400 mg of nilotinib, 400 mg of imatinib). The sensitivity analysis was made by introducing into the meta-
analysis: first, the results of 300 mg of nilotinib; second, the results of 400 mg of nilotinib; and third, the arithmetic mean of the results of the 2 nilotinib doses.
*National Cancer Institute Common Terminology Criteria for Adverse Events.
†M-H method, random-effects method.
‡Bold values in these columns are statistically significant.
§Pleural and pericardial effusion.
23 JUNE 2020 x VOLUME 4, NUMBER 12 FIRST-LINE IMATINIB VS OTHER TKIs IN CP CML 2731
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/4/12/2723/1745564/advancesadv2019001329.pdf by IST.  EU
R
O
PEO
 D
I O
N
C
O
LO
G
IA SR
L user on 10 July 2020
bosutinib in studies published up to July 2011 included only 4
RCTs.59 Although they also showed an advantage in using second-
generation TKIs on the basis of 12-month CCyR and MMR, they
could not make a meta-analysis of AEs because of the clinical
heterogeneity of the different drugs.59
The network meta-analysis by Signorovitch et al compared the
results obtained using first-line imatinib with those obtained using
nilotinib or dasatinib only on the basis of MMR by 12 months.60
Their 3 RCTs showed an advantage of nilotinib over imatinib and
dasatinib; there was no risk-of-bias assessment or quality grading of
the evidence.60
The study by Firwana et al compared MMR, MR4.5, OS, and PFS
after 12 months and at the time of the last FU in patients receiving
first-line imatinib with the results obtained using nilotinib, dasatinib,
bosutinib, or ponatinib in studies published up to January 2015,
including 6 RCTs.61 Although they showed that second- and third-
generation TKIs were better than imatinib in terms of MMR at
different time points, the results were not always statistically
significant; furthermore, they did not make a meta-analysis of AEs.61
The study by Yun et al compared CCyR and MMR, PFS, OS,
and progression to AP/BP CML after 12 months in patients
receiving first-line imatinib with the results obtained using nilotinib,
dasatinib, bosutinib, ponatinib, or radotinib in studies published up
to January 2016, including 8 RCTs.62 They showed an advantage of
new-generation TKIs in terms of 12-month MMR and progression to
AP/BP CML, but they did not make a meta-analysis of AEs.62
The network meta-analysis by Chen et al compared the results
obtained using first-line standard-dose imatinib with those obtained
using high-dose imatinib, nilotinib, dasatinib, or bosutinib in studies
published up to March 2018, including 14 RCTs. The considered
outcomes were 12-month CCyR; MMR after 12, 24 and 36 months;
deep molecular responses after 12, 24, 36, and 60 months; OS
and PFS; and grade 3 and 4 AEs.63 All of the drugs had an
advantage (direct comparison) over standard-dose imatinib in
terms of 12-month CCyR (except bosutinib), 12-month MMR,
MMR at 24 and 36 months (except high-dose imatinib), and deep
molecular responses at all time points (except bosutinib). There
was no difference in OS but PFS was better in the patients
receiving 400 mg of nilotinib. Standard-dose imatinib had the
most favorable toxicity profile. The main limitation of the study is
that it did not consider individual toxicities but only AEs as
a whole.63
The study by Douxfils et al considered occlusive vascular events as
the only primary outcome, and 1-year MMR and OS in studies
published up to October 2014.64 The protocol registered with
PROSPERO23 said that all patients treated with TKIs were included
in the study, with no restriction regarding previous therapy, and that
stratification by disease was planned to compare populations at similar
baseline risk. In the published paper, it was specified that the analysis
was restricted to a CML subgroup, but they did not say whether they
only considered newly diagnosed CP CML.64
In conclusion, on the basis of secondary efficacy outcomes, the
findings of our meta-analysis, supported by GRADE-assessed quality
evidence,28 suggest that patients with newly diagnosed CP CML
without comorbidities should receive second- or third-generation
TKIs; however, on the basis of toxicity outcomes, patients with
comorbidities should preferably be treated with imatinib. The use of
imatinib is further supported by the current availability of a cheaper
generic imatinib. Our data could be used to implement a health
technology assessment, and the updated RCT FU data may be
useful for making a meta-analysis of primary efficacy outcomes such
as OS and PFS after 60 months or more.
We cannot recommend a specific newer TKI because there are no
head-to-head RCTs: a network meta-analysis is required. The
definition of the optimal TKI for patients with newly CP CML should
consider AEs and comorbidities as well as molecular/cytogenetic
responses and transformation rates.
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